Business

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its 2025 financial results and provide a company update after the market closes on Tuesday, March 3, 2026.

articleCumberland Pharmaceuticals Inc.February 24, 20262/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-to-announce-2025-annual-financial-results-and-company-update
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE

About this update from Cumberland Pharmaceuticals Inc.

[{"type":"text","content":"NASHVILLE, Tenn., Feb. 24, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its 2025 financial results and provide a company update after the market closes on Tuesday, March 3, 2026.","length":280,"tagName":"p"},{"type":"text","content":"A conference call will be held on March 3 at 4:30 p.m. Eastern Time to discuss the results and update.","length":102,"tagName":"p"},{"type":"text","content":"The link to register is https://register-conf.media-server.com/register/BI6effc1a9cae9445f9bb0d60817870ffa.","length":107,"tagName":"p"},{"type":"text","content":"Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.","length":256,"tagName":"p"},{"type":"text","content":"A replay of the call will be available for one year and can be accessed via the Investor Relations page of Cumberland's website or by visiting https://edge.media-server.com/mmc/p/w5m9usns.","length":192,"tagName":"p"},{"type":"text","content":"Cumberland Pharmaceuticals is a specialty pharmaceutical company dedicated to providing uniqueproducts that improve patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments.","length":266,"tagName":"p"},{"type":"text","content":"The company's portfolio of FDA-approved brands includes:","length":60,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning;","length":84,"tagName":"p"}]},{"val":[{"type":"text","content":"Caldolor® (ibuprofen) injection, for the treatment of pain and fever;","length":69,"tagName":"p"}]},{"val":[{"type":"text","content":"Kristalose® (lactulose) for oral solution, a prescription laxative, for the treatment of constipation;","length":102,"tagName":"p"}]},{"val":[{"type":"text","content":"Sancuso® (granisetron) transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;","length":147,"tagName":"p"}]},{"val":[{"type":"text","content":"Vaprisol® (conivaptan)...

More updates from Cumberland Pharmaceuticals Inc.

Pharmaceuticals